Medifast Management
Management criteria checks 3/4
Medifast's CEO is Dan Chard, appointed in Oct 2016, has a tenure of 7.58 years. total yearly compensation is $7.04M, comprised of 14.2% salary and 85.8% bonuses, including company stock and options. directly owns 1.4% of the company’s shares, worth $3.84M. The average tenure of the management team and the board of directors is 4.2 years and 7.6 years respectively.
Key information
Dan Chard
Chief executive officer
US$7.0m
Total compensation
CEO salary percentage | 14.2% |
CEO tenure | 7.6yrs |
CEO ownership | 1.4% |
Management average tenure | 4.2yrs |
Board average tenure | 7.6yrs |
Recent management updates
Recent updates
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good
Aug 21Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year
Aug 09Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?
Jul 27What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Jul 12Medifast And Its Real Value
Jun 24Medifast: Growth And Value At A Reasonable Price
May 17Here's Why I Think Medifast (NYSE:MED) Might Deserve Your Attention Today
May 03CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | US$68m |
Dec 31 2023 | US$7m | US$1m | US$99m |
Sep 30 2023 | n/a | n/a | US$120m |
Jun 30 2023 | n/a | n/a | US$133m |
Mar 31 2023 | n/a | n/a | US$142m |
Dec 31 2022 | US$6m | US$981k | US$144m |
Sep 30 2022 | n/a | n/a | US$151m |
Jun 30 2022 | n/a | n/a | US$157m |
Mar 31 2022 | n/a | n/a | US$165m |
Dec 31 2021 | US$7m | US$914k | US$164m |
Sep 30 2021 | n/a | n/a | US$158m |
Jun 30 2021 | n/a | n/a | US$150m |
Mar 31 2021 | n/a | n/a | US$125m |
Dec 31 2020 | US$6m | US$909k | US$103m |
Sep 30 2020 | n/a | n/a | US$95m |
Jun 30 2020 | n/a | n/a | US$76m |
Mar 31 2020 | n/a | n/a | US$76m |
Dec 31 2019 | US$5m | US$843k | US$78m |
Sep 30 2019 | n/a | n/a | US$74m |
Jun 30 2019 | n/a | n/a | US$72m |
Mar 31 2019 | n/a | n/a | US$64m |
Dec 31 2018 | US$2m | US$675k | US$56m |
Sep 30 2018 | n/a | n/a | US$47m |
Jun 30 2018 | n/a | n/a | US$40m |
Mar 31 2018 | n/a | n/a | US$34m |
Dec 31 2017 | US$2m | US$650k | US$28m |
Compensation vs Market: Dan's total compensation ($USD7.04M) is above average for companies of similar size in the US market ($USD1.58M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Chard (58 yo)
7.6yrs
Tenure
US$7,039,062
Compensation
Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & CEO | 7.6yrs | US$7.04m | 1.4% $ 3.8m | |
Chief Financial Officer | 3.8yrs | US$2.01m | 0.069% $ 188.8k | |
Chief Business Operations Officer | 2.3yrs | US$1.61m | 0.074% $ 202.7k | |
Executive VP | 12.5yrs | US$1.63m | 0.073% $ 201.9k | |
Chief Field Operations Officer | 5.3yrs | US$1.70m | 0.061% $ 169.2k | |
VP of Finance & Chief Accounting Officer | 2.7yrs | no data | 0.0050% $ 13.6k | |
Vice President of Investor Relations | 1.2yrs | no data | no data | |
Chief Human Resources Officer | 4.6yrs | no data | no data |
4.2yrs
Average Tenure
52yo
Average Age
Experienced Management: MED's management team is considered experienced (4.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & CEO | 7.6yrs | US$7.04m | 1.4% $ 3.8m | |
Lead Independent Director | 8.9yrs | US$263.42k | 0.063% $ 173.1k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 5.9yrs | US$249.72k | 0.049% $ 135.2k | |
Independent Director | 4.9yrs | US$249.72k | 0.029% $ 80.6k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 5.9yrs | US$219.61k | no data | |
Chairman of Scientific Advisory Board | 15.5yrs | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 8.9yrs | US$252.44k | 0.043% $ 119.2k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
7.6yrs
Average Tenure
61.5yo
Average Age
Experienced Board: MED's board of directors are considered experienced (7.6 years average tenure).